[go: up one dir, main page]

SMT202100666T1 - Frazioni di plasma sanguigno come trattamento per disturbi cognitivi associati all'invecchiamento - Google Patents

Frazioni di plasma sanguigno come trattamento per disturbi cognitivi associati all'invecchiamento

Info

Publication number
SMT202100666T1
SMT202100666T1 SM20210666T SMT202100666T SMT202100666T1 SM T202100666 T1 SMT202100666 T1 SM T202100666T1 SM 20210666 T SM20210666 T SM 20210666T SM T202100666 T SMT202100666 T SM T202100666T SM T202100666 T1 SMT202100666 T1 SM T202100666T1
Authority
SM
San Marino
Prior art keywords
aging
treatment
blood plasma
cognitive disorders
plasma fractions
Prior art date
Application number
SM20210666T
Other languages
English (en)
Inventor
Vu Dang
David Bell
Ian Gallager
Steven P Braithwaite
S Sakura Minami
Joe Mccracken
Karoly Nikolich
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of SMT202100666T1 publication Critical patent/SMT202100666T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SM20210666T 2016-08-18 2017-04-27 Frazioni di plasma sanguigno come trattamento per disturbi cognitivi associati all'invecchiamento SMT202100666T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662376529P 2016-08-18 2016-08-18
US201662412258P 2016-10-24 2016-10-24
PCT/US2017/029953 WO2018034712A1 (en) 2016-08-18 2017-04-27 Blood plasma fractions as a treatment for aging-associated cognitive disorders
EP17841780.4A EP3484502B1 (en) 2016-08-18 2017-04-27 Blood plasma fractions as a treatment for aging-associated cognitive disorders

Publications (1)

Publication Number Publication Date
SMT202100666T1 true SMT202100666T1 (it) 2022-01-10

Family

ID=61196950

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210666T SMT202100666T1 (it) 2016-08-18 2017-04-27 Frazioni di plasma sanguigno come trattamento per disturbi cognitivi associati all'invecchiamento

Country Status (30)

Country Link
US (2) US20190321449A1 (it)
EP (2) EP3995140A1 (it)
JP (3) JP7316931B2 (it)
KR (3) KR20240036720A (it)
CN (2) CN115957309A (it)
AU (4) AU2017312722B2 (it)
BR (1) BR112019003172A2 (it)
CA (1) CA3033051A1 (it)
CL (1) CL2019000304A1 (it)
CY (1) CY1124695T1 (it)
DK (1) DK3484502T3 (it)
ES (1) ES2899147T3 (it)
HR (1) HRP20211628T1 (it)
HU (1) HUE056294T2 (it)
IL (2) IL264660B2 (it)
LT (1) LT3484502T (it)
MA (1) MA45692B1 (it)
MD (1) MD3484502T2 (it)
MX (2) MX2019001718A (it)
MY (1) MY202968A (it)
NZ (1) NZ750885A (it)
PL (1) PL3484502T3 (it)
PT (1) PT3484502T (it)
RS (1) RS62558B1 (it)
SG (1) SG11201901273TA (it)
SI (1) SI3484502T1 (it)
SM (1) SMT202100666T1 (it)
UA (1) UA126232C2 (it)
WO (1) WO2018034712A1 (it)
ZA (1) ZA202004834B (it)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200560A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2019222265A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
CN110787187B (zh) * 2018-07-16 2022-05-13 北京豪思生物科技股份有限公司 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用
CN110724176B (zh) * 2018-07-16 2021-10-26 北京豪思生物科技有限公司 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用
MX2021000707A (es) * 2018-07-20 2021-03-25 Alkahest Inc Regimen de dosificacion para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
SG11202103696XA (en) 2018-10-26 2021-05-28 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
CN110448686B (zh) * 2019-09-19 2022-11-04 北京豪思生物科技股份有限公司 铜蓝蛋白联合运铁蛋白的应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
EP4054597A4 (en) 2019-11-04 2024-02-21 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
WO2021102032A1 (en) 2019-11-20 2021-05-27 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US20220233587A1 (en) * 2021-01-06 2022-07-28 Yuvan Research, Inc. Anti-aging compositions and uses thereof
WO2023076679A1 (en) 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
AU2023378813A1 (en) * 2022-11-11 2025-05-29 Alkahest, Inc. Blood plasma fractions for improvement of myelination
WO2024258622A1 (en) * 2023-06-13 2024-12-19 Alkahest, Inc. Blood plasma fractions as a treatment for chemotherapy induced cognitive disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
EP1393740A4 (en) * 2001-05-11 2005-08-10 Juridical Foundation NEW MEANS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
US20040146565A1 (en) * 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
US20130121979A1 (en) * 2003-12-29 2013-05-16 Allan Mishra Method of treating cancer using platelet compositions
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
US20090297485A1 (en) * 2008-05-28 2009-12-03 Allan Mishra Compositions and methods for treating psychiatric and neurodegenerative disorders
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
WO2014182631A1 (en) * 2013-05-06 2014-11-13 Baxter International Inc. Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
MX2016007492A (es) 2013-12-09 2017-03-06 Univ Leland Stanford Junior Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento.
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2018200560A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Also Published As

Publication number Publication date
AU2017312722A1 (en) 2019-03-14
KR20190032614A (ko) 2019-03-27
JP7316931B2 (ja) 2023-07-28
UA126232C2 (uk) 2022-09-07
SI3484502T1 (sl) 2022-01-31
KR20220107322A (ko) 2022-08-02
PT3484502T (pt) 2021-11-18
BR112019003172A2 (pt) 2019-05-28
JP2019528269A (ja) 2019-10-10
HRP20211628T1 (hr) 2022-02-04
AU2021240142B2 (en) 2024-06-20
RS62558B1 (sr) 2021-12-31
IL264660A (it) 2019-04-30
AU2024219765A1 (en) 2024-10-10
ES2899147T3 (es) 2022-03-10
LT3484502T (lt) 2021-12-10
HUE056294T2 (hu) 2022-02-28
MX2019001718A (es) 2019-09-13
EP3484502A4 (en) 2020-03-04
JP7447069B2 (ja) 2024-03-11
AU2020200181B2 (en) 2021-07-22
SG11201901273TA (en) 2019-03-28
IL264660B1 (en) 2023-11-01
CL2019000304A1 (es) 2019-05-31
EP3995140A1 (en) 2022-05-11
PL3484502T3 (pl) 2022-01-31
MY202968A (en) 2024-05-31
NZ750885A (en) 2021-07-30
US20190321449A1 (en) 2019-10-24
ZA202004834B (en) 2022-07-27
DK3484502T3 (da) 2021-10-25
AU2021240142A1 (en) 2021-10-28
AU2020200181A1 (en) 2020-01-30
EP3484502A1 (en) 2019-05-22
US20220152161A1 (en) 2022-05-19
MA45692B1 (fr) 2021-10-29
AU2017312722B2 (en) 2020-01-02
MX2024008963A (es) 2024-07-30
JP2023156459A (ja) 2023-10-24
EP3484502B1 (en) 2021-08-25
CN115957309A (zh) 2023-04-14
MA45692A (fr) 2019-05-22
KR20240036720A (ko) 2024-03-20
CN109963582A (zh) 2019-07-02
CY1124695T1 (el) 2022-07-22
IL304946A (en) 2023-10-01
MD3484502T2 (ro) 2022-01-31
WO2018034712A1 (en) 2018-02-22
JP2022037124A (ja) 2022-03-08
CA3033051A1 (en) 2018-02-22
CN109963582B (zh) 2022-12-27
IL264660B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
ZA202004834B (en) Blood plasma fractions as a treatment for aging-associated cognitive disorders
IL288712A (en) Methods for treating abnormal movement disorders
EP3110416A4 (en) Amide compounds for treatment of complement mediated disorders
EP3283655A4 (en) Methods for treating myeloproliferative disorders
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
EP3119911A4 (en) Methods for treating neurological disorders
IL257908A (en) Methods for the treatment of epilepsy
IL267229A (en) Methods of treating ocular disorders
SG11201606307PA (en) A process for the preparation of a feedstock for a hydroprocessing unit
IL258137A (en) HIV treatment measures
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL259381B (en) Miravegron for the treatment of retinal diseases
HK40001252A (en) Blood plasma fractions as a treatment for aging-associated cognitive disorders
SI3903774T1 (sl) N,N-bis-2-merkaptoetil izoftalamid za zdravljenje nevrodegenerativnih bolezni
HK40087941A (en) Methods for the treatment of abnormal involuntary movement disorders
HK40035958B (en) Apparatus for treatment of brain disorders
ZA201707232B (en) Treatment of a hydrocarbon component
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201616286D0 (en) Plasma abatement
GB201616285D0 (en) Plasma abatement
HK1258518B (en) Gene therapy for ocular disorders